

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.

WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

GAU 1635/\$
Pre Amndt
5/B Linda

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC STEFFE
MICHAEL Q. LEE

JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER
JUDITH U. KIM
KEITH KIND
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
BARBARA A. PARVIS
MICHAEL A. RAHMAN*

STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*
JEFFREY T. HELVEY*
RICHARD A. DUNNING, JR.
KIMBERLIN L. MORLEY
RALPH P. ALBRECHT
HEIDI L. KRAUS*
JEFFREY R. KURIN*
CARL B. MASSEY, JR.*
RAYMOND MILLIEN*
PATRICK D. O'BRIEN*
BRIAN S. ROSENBLUM*

DONALD J. FEATHERSTONE**
LAWRENCE B. BUGAISKY**
KAREN R. MARKOWICZ**
GRANT E. REED**
VICTOR E. JOHNSON**
SERGE SIRA**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:

(202) 789-5525
INTERNET ADDRESS:

briand@skgf.com

July 23, 1998

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
Appl. No. 09/064,057; Filed: April 22, 1998
For: **Compositions and Methods for Reverse Transcription of Nucleic Acid
Molecules**
Inventors: GERARD *et al.*
Our Ref: 0942.4330002/RWE/BJD

RECEIVED
JUL 28 1998
GROUP 1800

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Fee Transmittal Form (PTO/SB/17) (*in duplicate*)
2. Second Preliminary Amendment;
3. Our check no. 22379 in the amount of \$104.00 to cover additional claim fees; and
4. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents
July 23, 1998
Page 2



The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


A handwritten signature in black ink, appearing to read "Brian J. Del Buono".

Brian J. Del Buono
Agent for Applicants
Registration No. P-42,473

BJD:aaw
Enclosures

P:\USERS\BRIAND\0942\4330002\072398.tm
SKGF Rev. 1/25/98 dcw

RECEIVED
JUL 28 1998
GROUP 1800



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL Patent fees are subject to annual revision on October 1. These are the fees effective October 1, 1997. Small Entity payments <i>must</i> be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12. See 37 C.F.R. §§ 1.27 and 1.28.		Compleat if Known	
TOTAL AMOUNT OF PAYMENT (\$) 104.00		Application Number	09/064,057
		Filing Date	April 22, 1998
		First Named Inventor	Gerard
		Examiner Name	To be assigned
		Group / Art Unit	1635
		Attorney Docket Number	0942.4330002/RWE/BJD

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)					
1. <input type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to: Deposit Account Number: 19-0036 Deposit Account Name: Sterne, Kessler, Goldstein & Fox P.L.L.C. <input type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 <input type="checkbox"/> Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance		3. ADDITIONAL FEES					
2. <input checked="" type="checkbox"/> Payment Enclosed: <input checked="" type="checkbox"/> Check No. 22379 <input type="checkbox"/> Money Order <input checked="" type="checkbox"/> Other* *Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036.							
FEE CALCULATION							
1. BASIC FILING FEE							
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid		
101	790	201	395	Utility filing fee			
106	330	206	165	Design filing fee			
107	540	207	270	Plant filing fee			
108	790	208	395	Reissue filing fee			
114	150	214	75	Provisional filing fee			
SUBTOTAL (1) (\$) -0-							
2. EXTRA CLAIM FEES							
Total Claims 64 - 63** = 43 X 22.00 = 22.00							
Indep. Claims 14 - 13** = 1 X 82.00 = 82.00							
Multiple Dependent Claims =							
** or number previously paid, if greater; For Reissues, see below							
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid		
103	22	203	11	Claims in excess of 20			
102	82	202	41	Independent claims in excess of 3			
104	270	204	135	Multiple dependant claim			
108	82	209	41	**Reissue independent claims over original patent			
110	22	210	11	**Reissue claims in excess of 20 and over original patent			
SUBTOTAL (2) (\$) 104.00							
		SUBTOTAL (3) (\$) -0-					

SUBMITTED BY				Complete (if applicable)	
Typed or Printed Name	Brian J. Del Buono			Reg. Number	P-42,473
Signature				Deposit Acct. User ID	
Date	July 23, 1998				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



5/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GERARD *et al.*

Appl. No.: 09/064,057

Filed: April 22, 1998

For: **Compositions and Methods for
Reverse Transcription of Nucleic
Acid Molecules**

Art Unit: 1635

Examiner: (To be Assigned)

Atty. Docket: 0942.4330002/RWE/BJD

Second Preliminary Amendment

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In advance of prosecution in the above identified matter, please amend the application
as follows:

In the Claims:

Please add the following new claim:

-- 116. An ASLV reverse transcriptase, wherein said ASLV reverse transcriptase is
reduced or substantially reduced in RNase H activity. --

RECEIVED
JUL 28 1998

GROUP 1800

07/27/1998 ZABDELLA 00000008 09064057

01 FC:103
02 FC:102

22.00 DP
82.00 DP

Remarks

Support for new claim 116 may be found throughout the specification as originally
filed, particularly at page 27, lines 7-13. Hence, the foregoing amendment does not add new
matter, and its entry is respectfully requested.